Search Results

THINK Surgical, Inc. announced that it will enter into a new Collaboration Agreement with b-ONE Ortho Corporation.

Ortho Development Corporation, a designer and manufacturer of orthopedic implants and instruments for hip and knee joint replacement surgery, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Trivicta™ Hip System.

QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”) announced completion of the transaction combining Quidel Corporation (“Quidel”) and Ortho Clinical Diagnostics Holdings plc (“Ortho”), creating QuidelOrtho, a leading in vitro diagnostics company.

Ending the diagnostic journey for patients, particularly those with rare diseases, improves patients’ quality of life while reducing costs to healthcare systems.

Ortho Development Corporation, a designer and manufacturer of orthopedic implants and instruments for hip and knee joint replacement surgery, today announced the launch of BKS® Uni, the latest addition to its portfolio of Balanced Knee® implant systems.

Ortho Clinical Diagnostics Holdings plc announced that based on a preliminary vote count by its proxy solicitor, Ortho shareholders have voted to approve the combination of the Company with Quidel Corporation pursuant to the Business Combination Agreement, dated December 22, 2021, by and among the Company, Quidel, and the other parties thereto.

DNA Diagnostics Center Partners with Contraline in ADAM TM Clinical Trial, Testing Revolutionary Male Contraceptive.

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, and Ortho Clinical Diagnostics Holdings plc (“Ortho”), one of the world’s larger pure-play in vitro diagnostics companies, announced today that the closing of the previously announced Ortho transaction is expected to occur on May 27, 2022.

Ortho Clinical Diagnostics Holdings plc, one of the world’s largest pure-play in-vitro diagnostics companies, announced financial results for the first quarter ended April 3, 2022.